Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 7.01, 9.01 · 8-K

Axe Compute Inc.

AGPUNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On November 9, 2026, following the review of his qualifications by the Board of Directors (the “Directors”) of Axe Compute Inc.…

Filed Nov 13, 2026Accepted Nov 13, 2026, 10:30 AM ESTCIK 1446159Accession 0001171843-26-007416
Share

Company context

We are a knowledge-driven company focused on applying artificial intelligence (“AI”) to support the discovery and development of optimal cancer therapies, which can ultimately lead to more effective treatments and improved patient outcomes. We use AI and our proprietary biobank of 150,000 tumor samples, categorized by tumor type, to provide actionable insights about drug compounds to improve the drug discovery process and increase the probability of drug compound success. We also create and develop tumor-specific 3D cell culture models mimicking the physiological environment of human tissue, enabling better-informed decision-making during drug development. Our suite of solutions supports oncology drug development from early discovery to clinical trials.

Current securities

Historical securities (2)

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsNov 2, 2026
  2. 4 filingOct 5, 2026
  3. Entry into a Material Definitive Agreement · Regulation FD DisclosureOct 5, 2026
  4. Entry into a Material Definitive Agreement · Completion of Acquisition or Disposition of AssetsSep 17, 2026
  5. 4 filingSep 9, 2026

Registered securities in this filing

Axe Compute Inc. · 8-K · Filed 2026-11-13

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.01 per share

Symbol
AGPU
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: Form8K

Dimensions: Not supplied

Accession 000117184326007416 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On November 9, 2026, following the review of his qualifications by the Board of Directors (the “Directors”) of Axe Compute Inc. (the “Company”), the Board appointed Guang Yang to fill an existing vacancy on the Board, effective immediately. Mr. Yang was appointed as a Class II director, to serve until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Following Mr. Yang’s appointment, the Board consists of five directors, a majority of whom are independent, and two vacancies remain. The Board has determined that Mr. Yang is independent under the listing rules of The Nasdaq Stock Market LLC (“Nasdaq”). There are no arrangements or understandings between Mr. Yang and any other person pursuant to which he was appointed as a director. There are no family relationships between Mr. Yang and any director or executive officer of the Company. Mr. Yang does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Mr. Yang will participate in the Company’s Amended and Restated Director Compensation Program (the “Director Compensation Program”), under which each non-employee director receives (i) a quarterly award of $8,333 for Board service, consisting of shares of the Company’s common stock with a value of $6,000 and $2,333 in cash, (ii) an additional annual award of $10,000, consisting of shares of common stock with a value of $7,000 and $3,000 in cash, payable on or about June 17 of each year, and (iii) an additional annual award of $11,112 for each committee on which the director serves, consisting of shares of common stock with a value of $8,000 and $3,112 in cash, payable on December 31 of each year, in each case with the cash portion payable in additional shares of common stock at the director’s election and with shares valued at the closing price of the common stock on the last day of the applicable quarter or year or other applicable award date. Mr. Yang’s compensation for his initial period of service will be prorated. Committee Appointment On November 9, 2026, the Board appointed Mr. Yang as a member and the chair of the Audit Committee of the Board and determined that Mr. Yang meets the heightened independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Nasdaq Listing Rule 5605(c)(2)(A), and qualifies as an “audit committee financial expert” as defined in Item 407(d)(5) of Regulation S-K. Biographical Information Guang Yang. Mr. Yang, age 62, has served as Managing Partner of FTL Investments LLC, an investment firm focused on innovative companies across sectors including lithium recycling and next-generation biotechnology, since July 2020. From 2018 to 2020, Mr. Yang served as Executive Chairman and Chief Executive Officer of BrightSphere Investment Group Inc. (NYSE: BSIG), an asset manager, having previously served as its Lead Independent Director from 2017 to 2018. From 2016 to 2018, Mr. Yang served as Partner and President of HNA North America and HNA Capital International. From 2010 to 2016, Mr. Yang founded and led Finergy Capital, a Beijing-based private investment firm, and from 1995 to 2010, he served as Executive Vice President and Senior Portfolio Manager of Global Equities at Franklin Templeton Investments and as Chairman of Franklin Templeton China. Mr. Yang holds a Ph. D. from the Australian National University, an M.B.A. from Harvard Business School and a B.S. from the University of Science and Technology of China, and has held the Chartered Financial Analyst designation since 1998. The Board believes Mr. Yang is qualified to serve as a director due to his extensive experience in capital markets and strategic corporate transformation and his experience as a senior executive and director of a U.S. public company.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 13, 2026, the Company issued a press release announcing the matters described in this Current Report on Form 8-K. A copy of the press release is furnished as Exhibit 99.1 hereto. The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.